Showing results (151-160 of 234) with videos related to
Sort By:
Pageof 24
JAMA Oncology|February 15, 2019
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical TrialDeborah W Bruner, Stephanie L Pugh, W Robert Lee, et al.Science Advances|July 3, 2026
Single-cell transcriptomic analysis reveals tumor-immune determinants of lymph node colonization and progression in thyroid cancerAnthony T Nguyen, Jolene Viramontes, Isaiah Vazquez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910Thomas M Pisansky, Daniel Hunt, Leonard G Gomella, et al.The Journal of Pathology|December 11, 2024
Stress testing deep learning models for prostate cancer detection on biopsies and surgical specimensBrennan T Flannery, Howard M Sandler, Priti Lal, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 22, 2019
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902Daniel A Hamstra, Stephanie L Pugh, Herbert Lepor, et al.Urologic Oncology|July 7, 2016
Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01Raymond H Mak, Daniel Hunt, Jason A Efstathiou, et al.JAMA Oncology|October 17, 2018
Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysisAmar U Kishan, Xiaoyan Wang, Wendy Seiferheld, et al.The New England Journal of Medicine|March 21, 2008
Quality of life and satisfaction with outcome among prostate-cancer survivorsMartin G Sanda, Rodney L Dunn, Jeff Michalski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate CancerW Robert Lee, James J Dignam, Mahul B Amin, et al.Pageof 24